

NIH Institutional Biosafety Committee Minutes National Institute of Environmental Health Sciences

Thursday, May 14, 2026

3:30 PM – 4:30 PM

Virtual via Teams

Members Present:

Quorum Met: Yes

☒	Francesco Demayo	Chair	☒	Huanchen Wang	Cell & Molecular Expert
☐	Christopher McGee	Biosafety Officer	☒	Lawrence Kirschner	Clinical Expert
☐	David Kurtz	Animal Expert	☐	Stephen Novak	Ex Officio
☒	Robert Petrovich	Protein Expression Expert	☒	John McLamb	Radiological Expert
☒	Justin Kosak	Lab Representative	☒	Jacqueline Hamilton	Community Representative
☒	Shih-Heng Chen	Virology Expert	☒	Troy Weaver	Community Representative
☒	Andrew Newell	Toxicology Expert			

Guests Present:

None

Announcements & Call to Order

- I. Meeting called to order by Francesco Demayo at 3:30pm.
- II. The IBC Chair identified no conflicts of interest for registrations under review.

Review of Past IBC Meeting Minutes

- I. April 16, 2026, Minutes
 - a. The April 2026 minutes were unanimously approved.

New Committee Business

- I. BSO or IBC lead reviewer preliminary registration approvals since the previous meeting.
 - a. None
- II. Registrations for Committee review

- a. New registration for committee review:

Registration Number, PI: B-1830, Paul Wade

- i. Reviewers: Andrew Newell
 - ii. Review Summary: The investigator aims to culture human mammary epithelial cell lines, MCF10A and MCF12A, which require supplementation with Cholera toxin (Ctx) at a low concentration. They will order 2mg lyophilized Ctx and reconstitute in a biosafety cabinet to [1mg/mL] to generate stock solution. Supplementation concentration in media will be approximately 100ng/mL. Cells will be used for protein and/or RNA analysis.
 - iii. Committee Discussion: It was discussed that there is no reliable human LD50 data for Ctx. Mouse and primate LD50 is generally considered 200-250ug/mL when administered intravenously, which is significantly more concentrated than the proposed working concentration. No sharps were to be used for any

procedures working with Ctx further mitigating risk from accidental intravenous exposure. The highest period of risk would be during reconstitution of the lyophilized Ctx and working with the stock solution. Work with established human cell lines should be conducted following universal precautions. Lab 1-2-3 and universal precautions posters should be displayed. Work should be done in a biosafety cabinet type II A2. PPE to include gloves, lab coat, eye protection, covered legs, closed toe shoes. 1:10 bleach to be used for decontamination and following standard biological waste disposal requirements consistent with institutional policy.

- iv. Training: Annual lab safety, bloodborne pathogen safety, and biosafety training must be maintained.
- v. Animal studies proposed: No.
- vi. The committee discussed and determined there is no dual-use or ePPP potential concerns related to these experiments.
- vii. Public comment: There were no concerns expressed with work described within the biosafety permit. No additional public comment was presented.
- viii. Work was approved at BSL-2 for eukaryotic work
- ix. Relevant sections of the NIH Guidelines: N/A
- x. A motion was made and seconded to approve the permit.
- xi. The committee unanimously approved as written.
 - 1. Conflicts of interest: None.
 - 2. Votes for: 10 Votes against: 0 Abstained: 0

- I. Committee Review of Inactivation Procedures
 - a. None

- II. Standard Operating Procedures/Plans
 - a. None

- III. Serious Adverse Events in Clinical Trials reviewed by the Committee
 - a. None

Reports

- I. Biosafety Officer Report –
 - a. Reported no incidents involving biohazardous work.
- II. Training-
 - a. Summer intern students have started their programs and are being onboarded weekly in batches. Facility safety, laboratory safety, biosafety and bloodborne pathogen training is being conducted on Mondays and Tuesdays and will last 4 weeks. Any students that are onboarded after this will be trained on an Ad hoc basis.

Around the Room/Committee Discussion

- I. None

Adjournment

- I. Meeting adjourned by Francesco Demayo at 3:42 pm

Next Meeting

- I. June 18th, 2026, virtual via Teams